Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.
Also called NCT01045447
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 465 participants
- Sponsor
- Registry
-
NCT01045447 -
2008-005767-34
-
- Other papers using this trial's data
- Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Croatia, France, India, Poland, South Africa, South Korea, Sweden, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01045447. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results posted on 2015-11-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
- Acronym
- BOOST™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01045447- Content hash
7de847335d7cdc38f8ccdaba00baa3d2214cf17fc0dd10d0bf05b4b2ef3796e6